These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32260556)

  • 1. Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas.
    Vazquez I; Papaleo N; Garcia E; Salido M; Salar A; Hernandez S; Calvo X; Colomo L
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma.
    Papaleo N; Climent F; Tapia G; Luizaga L; Azcarate J; Bosch-Schips J; Muñoz-Marmol AM; Salido M; Lome-Maldonado C; Vazquez I; Colomo L
    Virchows Arch; 2024 Aug; 485(2):307-314. PubMed ID: 37368083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
    Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A; Franco C; Comerma L; Hernandez S; Calvo X; Salar A; Climent F; Mate JL; Forcada P; Mozos A; Nonell L; Martinez A; Carrio A; Costa D; Dlouhy I; Salaverria I; Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E;
    Am J Surg Pathol; 2017 Jul; 41(7):877-886. PubMed ID: 28288039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas.
    Vazquez I; Papaleo N; Lop J; Puiggros A; Sanchez-Gonzalez B; Diez-Feijoo R; Gimeno E; Andrade-Campos M; Salar A; Espinet B; Salido M; Tapia G; Carreras J; Ferrer A; Arenillas L; Calvo X; Colomo L
    Virchows Arch; 2021 Dec; 479(6):1073-1078. PubMed ID: 33811533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Miyaoka M; Kikuti YY; Carreras J; Ikoma H; Hiraiwa S; Ichiki A; Kojima M; Ando K; Yokose T; Sakai R; Hoshikawa M; Tomita N; Miura I; Takata K; Yoshino T; Takizawa J; Bea S; Campo E; Nakamura N
    Mod Pathol; 2018 Feb; 31(2):313-326. PubMed ID: 28984304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD38, CD39, and BCL2 differentiate disseminated forms of high-grade B-cell lymphomas in biological fluids from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Marianini P; Lacheretz-Szablewski V; Almeras M; Moreaux J; Bret C
    Cytometry B Clin Cytom; 2024 Nov; 106(6):448-464. PubMed ID: 39295433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
    Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ
    Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 10. EBV
    Liu H; Xu-Monette ZY; Tang G; Wang W; Kim Y; Yuan J; Li Y; Chen W; Li Y; Fedoriw GY; Zhu F; Fang X; Luedke C; Medeiros LJ; Young KH; Hu S
    Histopathology; 2022 Feb; 80(3):575-588. PubMed ID: 34637146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.
    Bischin AM; Dorer R; Aboulafia DM
    Clin Med Insights Blood Disord; 2017; 10():1179545X17692544. PubMed ID: 28579851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
    Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
    Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM
    Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inferior survival in high-grade B-cell lymphoma with
    McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
    Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.
    Thirunavukkarasu B; Bal A; Prakash G; Malhotra P; Singh H; Das A
    Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):49-55. PubMed ID: 34456240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study).
    Hilton LK; Collinge B; Ben-Neriah S; Alduaij W; Shaalan H; Weng AP; Cruz M; Slack GW; Farinha P; Miyata-Takata T; Boyle M; Meissner B; Cook JR; Ondrejka SL; Ott G; Rosenwald A; Campo E; Amador C; Greiner TC; Raess PW; Song JY; Inghirami G; Jaffe ES; Weisenburger DD; Chan WC; Beiske K; Fu K; Delabie J; Pittaluga S; Iqbal J; Wright G; Sehn LH; Savage KJ; Mungall AJ; Feldman AL; Staudt LM; Steidl C; Rimsza LM; Morin RD; Scott DW
    Blood; 2024 Aug; 144(5):525-540. PubMed ID: 38701426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration.
    Rymkiewicz G; Grygalewicz B; Chechlinska M; Blachnio K; Bystydzienski Z; Romejko-Jarosinska J; Woroniecka R; Zajdel M; Domanska-Czyz K; Martin-Garcia D; Nadeu F; Swoboda P; Rygier J; Pienkowska-Grela B; Siwicki JK; Prochorec-Sobieszek M; Salaverria I; Siebert R; Walewski J
    Mod Pathol; 2018 May; 31(5):732-743. PubMed ID: 29327714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas.
    Huang W; Medeiros LJ; Lin P; Wang W; Tang G; Khoury J; Konoplev S; Yin CC; Xu J; Oki Y; Li S
    Mod Pathol; 2018 Sep; 31(9):1470-1478. PubMed ID: 29785017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.
    Baptista MJ; Tapia G; Muñoz-Marmol AM; Muncunill J; Garcia O; Montoto S; Gribben JG; Calaminici M; Martinez A; Veloza L; Martínez-Trillos A; Aldamiz T; Menarguez J; Terol MJ; Ferrandez A; Alcoceba M; Briones J; González-Barca E; Climent F; Muntañola A; Moraleda JM; Provencio M; Abrisqueta P; Abella E; Colomo L; García-Ballesteros C; Garcia-Caro M; Sancho JM; Ribera JM; Mate JL; Navarro JT
    Histopathology; 2022 Dec; 81(6):826-840. PubMed ID: 36109172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.